StockData
Marpai, Inc. logo

Marpai, Inc. (MRAI) company profile

MRAIOTCServices-Misc Health & Allied Services, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$3.18+0.05 (+1.60%)

Close on Oct 19, 2026Market cap $82.24MP/E –Yield –

About Marpai

Services-Misc Health & Allied Services, NEC, SIC 8090

Marpai, Inc. is a healthcare technology platform company operating subsidiaries that provide third-party administrator and pharmacy benefit management services. The business serves self-insured employers who directly fund employee healthcare programs, with a client base primarily comprising small and medium-sized enterprises as well as local government entities. Its activities span three main revenue streams: health plan administration, in-house ancillary offerings, and third-party vendor services. These solutions include custom benefit plan design, claims adjudication, clinical care navigation, out-of-network claims repricing, specialty drug savings, and comprehensive pharmacy benefit management.

The company focuses its operations on the self-funded healthcare sector across the United States and maintains an Israeli operating subsidiary known as EYME Technologies, Ltd. As of December 31, 2025, Marpai engaged a workforce of 107 full-time employees. The company maintains its principal executive offices and headquarters in Tampa, Florida.

Summary of the business section of Marpai's latest annual report, written by StockData.

Company profile

Company

Legal name
Marpai, Inc.
Headquarters
Tampa, FL
Address
615 Channelside Drive, Suite 207 33602
Phone
(646) 303-3483
Employees
107, Dec 31, 2025
Industry
Services-Misc Health & Allied Services, NEC
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
UHY LLP, Melville, New York

Stock & identifiers

Ticker
MRAI
Exchange
OTC
IPO date
Oct 28, 2021
Shares outstanding
27M, Aug 13, 2026
Public float
$9.75M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-4 reverse, Jun 29, 2023
SEC CIK
1844392
CUSIP
571354109
ISIN
US5713541093
FIGI
BBG011WQW2R4
Share class FIGI
BBG011WQW3M7
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Damien LamendolaChief Executive Officer, Director2,581,674
Steve Andrew JohnsonChief Financial Officer1,024,192
Dallas ScripChief Operating Officer400,000
John Paul PowersPresident410,000
Colleen DiClaudioDirector267,500
Sagiv ShivDirector613,667
Robert M. PonsDirector484,200
Jennifer Rosario CalabreseDirector225,000
Yaron EitanDirector1,224,073

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.21M$1.16M$1.26M$19–
FY2024$362.00K$712.00K$514.00K$25–
FY2023$292.00K$288.00K$2.29M$53–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsTotalvs. prior year
Damien Lamendola
Chief Executive Officer and Director
–$362$362–
Steve Johnson
Chief Financial Officer
$39$211$250–
John Powers
President and Chief Operating Officer
$150$78$228–
Gonen Antebi
Chief Operating Officer
$36–$36-91%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 28, 2021
Offer price
$4.00
Securities offered
6,250,000
Gross proceeds
$25.00M
Exchange
Nasdaq
First trading day
Oct 27, 2021
First-day close
$4.75+18.8%
Lock-up ends (est.)
Apr 25, 2022

“The initial public offering price of our shares is $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“we had a total of 107 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?